CPMVMosaic ImmunoEngineering Inc.

About Mosaic ImmunoEngineering Inc. (CPMV)

Mosaic ImmunoEngineering Inc. (CPMV) is a Biotechnology company headquartered in Huntington Beach, CA, United States whose shares trade over-the-counter on the Pink tier.

Mosaic ImmunoEngineering Inc. is a development-stage biotechnology company focused on advancing and eventually commercializing our proprietary immunomodulator platform technology. Our lead immunomodulator product candidate, MIE-101, is based on a naturally occurring plant virus known as Cowpea mosaic virus (or CPMV) which is believed to be non-infectious in animals including mice, dogs and humans. However, because of its virus structure and genetic composition, CPMV elicits a strong immune response when delivered directly into tumors as shown in our preclinical studies. Data from numerous mouse cancer models and in companion dogs with naturally occurring tumors show the ability of intratumoral ("IT") administration of CPMV to result in anti-tumor effects in treated tumors and systemically at other sites of disease through immune activation.

Products and services

Developing products to treat cancer and infectious diseases.

CPMV key facts

Ticker symbol

CPMV

Market tier

Pink

Sector

Healthcare

Industry

Biotechnology

Headquarters

Huntington Beach, CA, United States

Country of incorporation

US

Employees

8

Estimated market cap

$4.54M (as of Apr 11, 2025)

Shares outstanding

7,242,212

Reporting standard

U.S. Reporting: SEC Reporting

Audit status

Audited

Fiscal year end

12/31

Mosaic ImmunoEngineering Inc. leadership

• Steven W. King — CEO, President
• Paul J. Lytle — CFO, Corporate Secretary
• Jay Carlson — Senior IR Manager

Explore more: Biotechnology stocks · Healthcare sector · Pink stocks · OTC stocks starting with C